Call for Papers  

Article Details


Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease

[ Vol. 16 , Issue. 25 ]

Author(s):

Miguel Medina and Jesus Avila   Pages 2790 - 2798 ( 9 )

Abstract:


Originally discovered because of its role in the regulation of glucose metabolism, Glycogen Synthase Kinase-3 (GSK-3) is now recognised as a crucial player in a diverse series of cellular processes involved in Alzheimers disease (AD) pathology. Besides having been identified as the major tau protein kinase, GSK-3 mediates Aβ neurotoxicity, plays an essential role in synaptic plasticity and memory, might be involved in Aβ formation, and it has an important role in inflammation and neuronal survival, all key features of AD neuropathology. Moreover, AD was one of the earliest disorders linked to GSK-3 dysfunction. Thus, the discovery of small molecule GSK-3 inhibitors has attracted significant attention to the protein both as for the therapeutic intervention in neurodegenerative diseases as well as a means to understand the molecular basis of these disorders.

Keywords:

GSK-3,Alzheimer's disease,Tau,amyloid,neurodegeneration,lithium,memory,neuroinflammation

Affiliation:

, Centro de Biologia Molecular “Severo Ochoa” Universidad Autonoma de Madrid, Nicolas Cabrera, 1, Campus de Cantoblanco, 28049 - Madrid, Spain.



Read Full-Text article